Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;7(6):655-662.
doi: 10.1111/1759-7714.12381. Epub 2016 Aug 1.

Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer

Hisao Imai  1 , Keita Mori  2 , Nodoka Watase  3 , Toshifumi Kazama  4 , Sakae Fujimoto  5 , Kyoichi Kaira  6 , Masanobu Yamada  7 , Koichi Minato  5
Affiliations

Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer

Hisao Imai et al. Thorac Cancer. 2016 Nov.

Abstract

Background: The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small-cell lung cancer (SCLC). Therefore, the objective of our study was to determine the relationships between progression-free survival (PFS) or post-progression survival (PPS) and OS after first-line chemotherapy in elderly patients with extensive disease-SCLC (ED-SCLC), using individual level data.

Methods: Between July 1998 and December 2014, we analyzed 57 cases of elderly patients with ED-SCLC who were treated with carboplatin and etoposide as first-line chemotherapy. The relationships between PFS and PPS with OS were analyzed at an individual level.

Results: Spearman rank correlation and linear regression analyses showed that PPS was strongly correlated with OS (r = 0.92, P < 0.05, R 2 = 0.83) and PFS was moderately correlated with OS (r = 0.76, P < 0.05, R 2 = 0.25). The best response at second-line treatment and the number of regimens after progression beyond first-line chemotherapy were both significantly associated with PPS (P < 0.05).

Conclusions: PPS has a stronger impact on OS than PFS in elderly ED-SCLC patients after first-line chemotherapy. In addition, the response at second-line treatment and the number of additional regimens after first-line treatment are significant independent prognostic factors for PPS. These results suggest that OS in elderly ED-SCLC patients may be influenced by treatments subsequent to first-line chemotherapy; however, this remains to be verified with prospective studies.

Keywords: Elderly; extensive disease small-cell lung cancer; overall survival; post-progression survival; progression-free survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Kaplan–Meier plots showing progression‐free survival (PFS). Median PFS: 4.2 months. (b) Kaplan–Meier plots showing overall survival (OS). Median overall survival: 8.2 months. (#) There was 1 outlier in these data.
Figure 2
Figure 2
(a) Correlation between overall survival (OS) and progression‐free survival (PFS). (b) Correlation between overall survival (OS) and post‐progression survival (PPS). (#) There were 2 outliers in these data. *The r values represent Spearman's rank correlation coefficient. **The R2 values represent linear regression.
Figure 3
Figure 3
Progression‐free survival (PFS) and post‐progression survival (PPS) in the overall population.
Figure 4
Figure 4
(a) Kaplan‐Meier plots showing post‐progression survival (PPS), according to the best response following second‐line treatment. Non‐progressive disease (non‐PD), median = 7.8 months; progressive disease (PD), median = 3.7 months. (b) Kaplan–Meier plots showing post‐progression survival (PPS), according to the number of regimens after progression. No further regimen, median = 1.5 months; 1 regimen, median = 4.4 months; ≥ 2 regimens, median = 8.3 months. (#) There was 1 outlier in these data.
See this image and copyright information in PMC

References

    1. DeSantis CE, Lin CC, Mariotto AB et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252–71. - PubMed
    1. Kalemkerian GP, Akerley W, Bogner P et al. Small cell lung cancer. J Natl Compr Canc Netw 2013; 11: 78–98. - PMC - PubMed
    1. National Cancer Institute at the National Institutes of Health . Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version 2015.
    1. Johnson BE, Jänne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 2004; 18: 309–22. - PubMed
    1. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive‐stage small cell lung carcinoma: Current status and future prospects. Eur Respir J 2010; 35: 202–15. - PubMed

LinkOut - more resources